Abstract: Provided herein are trispecific antigen-binding proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to a target antigen. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such trispecific antigen-binding proteins. Also disclosed are methods of using the disclosed trispecific antigen-binding proteins in the prevention, and/or treatment diseases, conditions and disorders.

Abstract: Provided herein are trispecific antigen-binding proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to a target antigen. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such trispecific antigen-binding proteins. Also disclosed are methods of using the disclosed trispecific antigen-binding proteins in the prevention, and/or treatment diseases, conditions and disorders.

Abstract: Provided herein are trispecific antigen-binding proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to a target antigen. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such trispecific antigen-binding proteins. Also disclosed are methods of using the disclosed trispecific antigen-binding proteins in the prevention, and/or treatment diseases, conditions and disorders.

Abstract: Provided herein are trispecific antigen-binding proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to a target antigen. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such trispecific antigen-binding proteins. Also disclosed are methods of using the disclosed trispecific antigen-binding proteins in the prevention, and/or treatment diseases, conditions and disorders.

Abstract: Provided herein are trispecific antigen-binding proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to a target antigen. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such trispecific antigen-binding proteins. Also disclosed are methods of using the disclosed trispecific antigen-binding proteins in the prevention, and/or treatment diseases, conditions and disorders.

Abstract: The present invention provides chimeric and humanized antibodies that specifically recognize ?5?1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.

Abstract: The invention relates to the identification and generation of antibodies that bind to TMEFF2 proteins which are involved in cancer. Further, the invention provides for the use of these antibodies in the treatment of cancer.

Abstract: The present invention provides chimeric and humanized antibodies that specifically recognize ?5?1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.

Abstract: The present invention provides chimeric and humanized antibodies that specifically recognize ?5?1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.

Abstract: The present invention provides chimeric and humanized antibodies that specifically recognize ?5?1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.

Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.

Abstract: The present invention provides chimeric and humanized antibodies that specifically recognize ?5?1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.

Abstract: The present invention provides methods for direct killing of cancer cells using anti-?5?1 antibodies. Generally, the method comprises contacting a cancer cell that expresses ?5?1 on its surface with an anti-?5?1 antibody, and thereby inducing the death of the cancer cell. The methods of the invention may be employed at an early stage of cancer development in a patient to prevent tumor establishment. In addition, the methods may be used to treat previously formed tumors especially in cancer that have not proven susceptible to anti-angiogenesis therapy. The methods may be employed as a combination therapy of anti-?5?1 antibodies together with cancer chemotherapeutic agents or other molecular-based cancer therapeutic agents.

Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.

Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.

Abstract: The present invention provides chimeric and humanized antibodies that specifically recognize ?5?1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.

Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.

Abstract: The present invention provides methods for direct killing of cancer cells using anti-?5?1 antibodies. Generally, the method comprises contacting a cancer cell that expresses ?5?1 on its surface with an anti-?5?1 antibody, and thereby inducing the death of the cancer cell. The methods of the invention may be employed at an early stage of cancer development in a patient to prevent tumor establishment. In addition, the methods may be used to treat previously formed tumors especially in cancer that have not proven susceptible to anti-angiogenesis therapy. The methods may be employed as a combination therapy of anti-?5?1 antibodies together with cancer chemotherapeutic agents or other molecular-based cancer therapeutic agents.

Abstract: The present invention provides chimeric and humanized antibodies that specifically recognize ?5?1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.

Abstract: Pharmaceutical combinations comprising an ?5?1 antagonist in combination with a tyrosine kinase inhibitor. In some embodiments, the ?5?1 antagonist is volociximab. In some embodiments, the tyrosine kinase inhibitor is sunitinib or a pharmaceutically acceptable salt thereof. The invention also relates to methods for treating cancer by administering the pharmaceutical combinations to a subject.